Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kingsoft Cloud Holdings Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Kingsoft Cloud Holdings Limited trades at $10.52 (market cap $2.80B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | KC | |
|---|---|---|
Market Cap | $4.49B | $2.80B |
Sector | Health | Technology |
52-Week High | $28.06 | $18.21 |
52-Week Low | $20.06 | $8.58 |
Enterprise Value | $3.69B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kingsoft Cloud (KC) trades at $9.13 with a slight 0.33% daily gain, showing technical bearish signals despite recent earnings beats. The company reported $9.56B revenue for 2025 but continues to post net losses (-$936M), though AI-driven cloud demand is accelerating growth. Analyst sentiment remains positive with 70% buy ratings, while technical indicators show mixed signals with RSI levels suggesting potential oversold conditions.
KC presents a growth story fueled by AI cloud services expansion, but profitability challenges and negative margins create investor uncertainty. The stock's appeal hinges on management's ability to convert revenue growth into sustainable profits amid heavy infrastructure investments. Near-term catalysts include Q2 2026 earnings and margin improvement progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
